Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma

Journal of Immunology

Volumn 185, Issue 2, 2010, Pages 956-966

  Anraku, Masaki ^a   Tagawa, Tetsuzo ^a   Wu, Licun ^a   Yun, Zhihong ^a   Keshavjee, Shaf ^a   Zhang, Li ^a   Johnston, Michael R ^b   De Perrot, Marc ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; PEMETREXED; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; MALIGNANT MESOTHELIOMA; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; CBA MOUSE; CYTOLOGY; IMMUNOLOGY; MESOTHELIOMA; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PLEURA TUMOR; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ANTIGENS, CD8; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GLUTAMATES; GUANINE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MICE, INBRED NOD; MICE, SCID; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 77955483885     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900437     Document Type: Article

References (39)

1. Robinson, B. W., and R. A. Lake. 2005. Advances in malignant mesothelioma. N. Engl. J. Med. 353: 1591-1603.
2. Sugarbaker, D. J., R. M. Flores, M. T. Jaklitsch, W. G. Richards, G. M. Strauss, J. M. Corson, M. M. DeCamp, Jr., S. J. Swanson, R. Bueno, J. M. Lukanich, E. H. Baldini, and S. J. Mentzer. 1999. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117: 54-63; discussion 63-55.
3. Weder, W., P. Kestenholz, C. Taverna, S. Bodis, D. Lardinois, M. Jerman, and R. A. Stahel. 2004. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 22: 3451-3457.
4. Flores, R. M. 2005. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 49(Suppl 1): S71-S74.
5. de Perrot, M., R. Feld, J. Cho, A. Bezjak, M. Anraku, R. Burkes, H. Roberts, M. S. Tsao, N. Leighl, S. Keshavjee, and M. R. Johnston. 2009. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27: 1413-1418.
6. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
7. Yu, P., and Y. X. Fu. 2006. Tumor-infiltrating T lymphocytes: friends or foes? Lab. Invest. 86: 231-245.
8. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
9. Gao, Q., S. J. Qiu, J. Fan, J. Zhou, X. Y. Wang, Y. S. Xiao, Y. Xu, Y. W. Li, and Z. Y. Tang. 2007. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25: 2586-2593.
10. Woo, E. Y., C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, and C. H. June. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
11. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
12. Anraku, M., K. S. Cunningham, Z. Yun, M. S. Tsao, L. Zhang, S. Keshavjee, M. R. Johnston, and M. de Perrot. 2008. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 135: 823-829.
13. Nowak, A. K., R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger, and B. W. Robinson. 2003. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170: 4905-4913.
14. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234.
15. Nowak, A. K., B. W. Robinson, and R. A. Lake. 2003. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63: 4490-4496.
16. Yang, S., and F. G. Haluska. 2004. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J. Immunol. 172: 4599-4608.
17. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
18. Vogelzang, N. J., J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, et al. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21: 2636-2644.
19. Davis, M. R., L. S. Manning, D. Whitaker, M. J. Garlepp, and B. W. Robinson. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52: 881-886.
20. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59: 3128-3133. (Pubitemid 29316012)
21. Teicher, B. A., V. Chen, C. Shih, K. Menon, P. A. Forler, V. G. Phares, and T. Amsrud. 2000. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. 6: 1016-1023.
22. Wang, H., E. R. Rayburn, W. Wang, E. R. Kandimalla, S. Agrawal, and R. Zhang. 2006. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol. Cancer Ther. 5: 1585-1592.
23. Lowenthal, J. W., P. Corthésy, C. Tougne, R. Lees, H. R. MacDonald, and M. Nabholz. 1985. High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol. 135: 3988-3994.
24. Ortega, G., R. J. Robb, E. M. Shevach, and T. R. Malek. 1984. The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J. Immunol. 133: 1970-1975.
25. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
26. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
27. Beyer, M., and J. L. Schultze. 2006. Regulatory T cells in cancer. Blood 108: 804-811.
28. Kim, R., M. Emi, K. Tanabe, and K. Arihiro. 2006. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66: 5527-5536. (Pubitemid 43927099)
29. Hegmans, J. P., J. D. Veltman, M. E. Lambers, I. J. de Vries, C. G. Figdor, R. W. Hendriks, H. C. Hoogsteden, B. N. Lambrecht, and J. G. Aerts. 2010. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med. doi:10.1164/rccm. 200909-1465OC.
30. hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J. Clin. Invest. 119: 2648-2662.
31. Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8: 59-73.
32. van der Most, R. G., A. J. Currie, A. L. Cleaver, J. Salmons, A. K. Nowak, S. Mahendran, I. Larma, A. Prosser, B. W. Robinson, M. J. Smyth, et al. 2009. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS ONE 4: e6982.
33. Zitvogel, L., L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer. 2008. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118: 1991-2001.
34. Rudge, G., S. P. Barrett, B. Scott, and I. R. van Driel. 2007. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells. J. Immunol. 178: 4089-4096. (Pubitemid 46492357)
35. Suzuki, E., V. Kapoor, H. K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda. 2004. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin. Cancer Res. 10: 5907-5918.
36. Wahl, S. M., J. Wen, and N. Moutsopoulos. 2006. TGF-beta: a mobile purveyor of immune privilege. Immunol. Rev. 213: 213-227.
37. Wallace, A., V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda. 2008. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 14: 3966-3974.
38. Biswas, S., M. Guix, C. Rinehart, T. C. Dugger, A. Chytil, H. L. Moses, M. L. Freeman, and C. L. Arteaga. 2007. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117: 1305-1313.
39. Shih, C., V. J. Chen, L. S. Gossett, S. B. Gates, W. C. MacKellar, L. L. Habeck, K. A. Shackelford, L. G. Mendelsohn, D. J. Soose, V. F. Patel, et al. 1997. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57: 1116-1123.